This article is more than 5 years old. Information may no longer be current.
Efficacy of triple therapy varied among Israeli patients with HCV
Click Here to Manage Email Alerts
WASHINGTON, D.C. — Israeli patients with hepatitis C virus infection genotype 1 showed varied improvements after protease inhibitor-based triple therapy, according to data presented at ICAAC 2014.
Researchers, including Gil Ben yakov, MD, at the Soroka Medical Center in southern Israel treated 55 outpatients with hepatitis C virus (HCV) genotype 1 with telaprevir (n=39) or boceprevir (n=16) in combination with pegylated interferon and ribavirin between September 2011 and November 2013. Patients were followed for 6 months post-treatment.
Gil Ben yakov
Overall, 34 patients (61.8%) achieved sustained virologic response (SVR). Forty-seven percent of all patients with genotype 1A, 71% of all patients with genotype 1B, 63.6% of all patients with mild or no fibrosis (F0-F2) and 63% of all patients with advanced fibrosis (F3-F4) achieved SVR. Treatment-naive patients (57%), patients who experienced a previous relapse (83.3%) and nonresponders (57.1%) met SVR at 6 months while assigned triple therapy.
“The first generation DAA-based triple therapy today can still today be a reasonable therapeutic option for HCV patients," Ben yakov told Healio.com/Hepatology. "It is [countries with limited resources] whose health budget cannot afford the huge expense of the new regimes.” – by Melinda Stevens
For more information:
Ben yakov G. Abstract V-479. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept. 5-9, 2014; Washington, D.C.
Disclosure: The researchers report no relevant financial disclosures.